412 related articles for article (PubMed ID: 20819751)
1. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
3. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Sakuma M; Shirato K
Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
[TBL] [Abstract][Full Text] [Related]
4. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
Jing ZC; Yu ZX; Shen JY; Wu BX; Xu KF; Zhu XY; Pan L; Zhang ZL; Liu XQ; Zhang YS; Jiang X; Galiè N;
Am J Respir Crit Care Med; 2011 Jun; 183(12):1723-9. PubMed ID: 21471085
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil for the treatment of pulmonary arterial hypertension.
Rosenzweig EB
Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
10. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Fan YF; Zhang R; Jiang X; Wen L; Wu DC; Liu D; Yuan P; Wang YL; Jing ZC
Cardiovasc Res; 2013 Aug; 99(3):395-403. PubMed ID: 23650288
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
12. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
Jing ZC; Jiang X; Wu BX; Xu XQ; Wu Y; Ma CR; Wang Y; Yang YJ; Pu JL; Gao W
Heart; 2009 Sep; 95(18):1531-6. PubMed ID: 19549620
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil for the treatment of pulmonary arterial hypertension.
Klinger JR
Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
Schwartz BG; Kloner RA
Circulation; 2010 Jul; 122(1):88-95. PubMed ID: 20606131
[No Abstract] [Full Text] [Related]
16. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
17. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
18. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Channick R; Preston I; Klinger JR
Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
[TBL] [Abstract][Full Text] [Related]
19. Use of phosphodiesterase-5 inhibitors by college students.
Freitas VM; Menezes FG; Antonialli MM; Nascimento JW
Rev Saude Publica; 2008 Oct; 42(5):965-7. PubMed ID: 18797570
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Chaumais MC; Perrin S; Sitbon O; Simonneau G; Humbert M; Montani D
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1193-205. PubMed ID: 23944387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
